{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+s.c.&page=4", "query": { "intervention": "Placebo, s.c.", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 239, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+s.c.&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+s.c.&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T22:43:30.138Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00223691", "title": "Treatment of Orthostatic Hypotension in Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autonomic Failure", "Orthostatic Hypotension" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Acarbose", "type": "DRUG" }, { "name": "Pyridostigmine Bromide", "type": "DRUG" }, { "name": "Yohimbine", "type": "DRUG" }, { "name": "Midodrine HCl", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Modafinil", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "water intake", "type": "OTHER" }, { "name": "Diphenhydramine Hydrochloride", "type": "DRUG" }, { "name": "Ranitidine HCL", "type": "DRUG" }, { "name": "Tranylcypromine", "type": "DRUG" }, { "name": "Ergotamine/ Caffeine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Pseudoephedrine", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Oxymetazoline 0.05% nasal solution", "type": "DRUG" }, { "name": "Bovril", "type": "DIETARY_SUPPLEMENT" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "Rivastigmine tartrate", "type": "DRUG" }, { "name": "Carbidopa/levodopa", "type": "DRUG" }, { "name": "Inflatable abdominal binder", "type": "DEVICE" }, { "name": "inflatable abdominal binder (sham)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 389, "start_date": "2002-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223691" }, { "nct_id": "NCT03086330", "title": "Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2017-03-15", "completion_date": "2018-08-06", "has_results": true, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 43, "location_summary": "Andalusia, Alabama • Anniston, Alabama • Glendale, Arizona + 38 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086330" }, { "nct_id": "NCT06717698", "title": "A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "NNC0519-0130", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 465, "start_date": "2024-12-02", "completion_date": "2026-09-17", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 18, "location_summary": "San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more", "locations": [ { "city": "San Dimas", "state": "California" }, { "city": "San Ramon", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06717698" }, { "nct_id": "NCT04876391", "title": "A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Spesolimab 1200 mg", "type": "DRUG" }, { "name": "Spesolimab 600 mg", "type": "DRUG" }, { "name": "Placebo matching 600 mg Spesolimab", "type": "DRUG" }, { "name": "Placebo matching 1200 mg Spesolimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-08-24", "completion_date": "2024-04-26", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 4, "location_summary": "Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04876391" }, { "nct_id": "NCT01377012", "title": "Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Secukinumab (AIN457)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 637, "start_date": "2011-08-30", "completion_date": "2015-09-09", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 39, "location_summary": "Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01377012" }, { "nct_id": "NCT06409130", "title": "Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol-related Liver Disease" ], "interventions": [ { "name": "NNC0194-0499", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "NNC0194-0499 placebo", "type": "DRUG" }, { "name": "Semaglutide placebo (Group A)", "type": "DRUG" }, { "name": "Cagrilintide + semaglutide", "type": "DRUG" }, { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Cagrilintide placebo", "type": "DRUG" }, { "name": "Semaglutide placebo (Group B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2024-05-20", "completion_date": "2026-01-12", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 29, "location_summary": "Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06409130" }, { "nct_id": "NCT04279613", "title": "A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type I Diabetes" ], "interventions": [ { "name": "NNC0361-0041", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 47, "start_date": "2020-11-23", "completion_date": "2024-04-24", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 16, "location_summary": "Orange, California • San Francisco, California • Stanford, California + 13 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04279613" }, { "nct_id": "NCT01807520", "title": "Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Nail Psoriasis" ], "interventions": [ { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2013-06-20", "completion_date": "2017-01-03", "has_results": true, "last_update_posted_date": "2018-03-13", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807520" }, { "nct_id": "NCT01537432", "title": "Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis, Plaque-type Psoriasis" ], "interventions": [ { "name": "secukinumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2012-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-01-05", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pasadena", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Windsor", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01537432" }, { "nct_id": "NCT07567001", "title": "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity", "Heart Failure" ], "interventions": [ { "name": "NNC0487-0111", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5610, "start_date": "2026-05-11", "completion_date": "2029-08-15", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-04T22:43:30.138Z", "location_count": 206, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07567001" } ] }